A Phase 1 open-label study to identify a dosing regimen of the pan-AKT inhibitor AZD5363 for evaluation in solid tumors and in PIK3CA-mutated breast and gynecologic cancers.
| Image |  |
|---|---|
| Description | scientific article published on 24 October 2017 |
| Author/s |
author: Udai Banerji Philippe L. Bedard Vicky Rowlands Thomas Carr Justin Lindemann J Pérez Fidalgo Shannon N. Westin |
| Publication date | October 24, 2017 |
| Language | English |
| Country of origin | |
| Wikipedia link | |
| Copyright status | |
| Missing/wrong data? | Edit Wikidata item |